# Corvus Pharmaceuticals' R&D Spending Rises to $17.8 Million in Q3

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/51725
Published: 2026-11-08T17:55:12.000Z
Updated: 2026-11-08T17:55:12.000Z
Section: Business

> Expenses were $8.5 million in the year-earlier quarter, Chief Financial Officer Leiv Lea said.

Leiv Lea, chief financial officer of Corvus Pharmaceuticals, said research and development expenses totaled $17.8 million in the third quarter of 2026. The company recorded $8.5 million in those expenses in the same quarter of 2025.